CLSDQ — Clearside Biomedical, Share News
0.000.00%
Last trade - 00:00- $1.31m
- $55.68m
- $1.66m
Brief: Clearside Biomedical Announces Plans For Phase 2B Trial Of Cls-Ax In Wet AMD
Clearside Biomedical Inc reports results for the quarter ended in December - Earnings Summary
Brief: Clearside Biomedical Announces Fourth Quarter And Full Year 2022 Financial Results
Clearside Biomedical Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Clearside Biomedical Announces Leadership Team Update
Brief: Clearside Biomedical Has About $48.3 Mln Of Cash, Cash Equivalents
Brief: Clearside Biomedical Announces 6-Month Results From Oasis Extension Study
U.S. RESEARCH ROUNDUP-Amyris, HanesBrands, Roblox
U.S. STOCKS ON THE MOVE-Wendy's, Corebridge, Riskified
U.S. STOCKS ON THE MOVE-Trade Desk, PolarityTE, Axon, Disney, Meta
Clearside Biomedical slips on lower Q3 revenue, wider-than-expected loss
Clearside Biomedical Inc reports results for the quarter ended in September - Earnings Summary
U.S. STOCKS ON THE MOVE-Tesla, Canopy Growth, Merrimack Pharma
Clearside Biomedical up on positive data from eye disorder drug trial
Brief: Clearside Biomedical Announces Positive Results In Oasis Phase 1/2A Clinical Trial Of Suprachoroidal Cls-Ax In Wet AMD Patients
Brief: Clearside Biomedical Announces Q3 2022 Financial Results
Brief: Clearside Biomedical To Report Oasis Phase 1/2A Clinical Trial Results And Host Conference Call On Wednesday, November 9, 2022 In Conjunction With Third Quarter 2022 Financial Results
Clearside Biomedical Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Clearside Biomedical To Report Q3 Results On November 9